Neuroprotective activity of dimer of 16,16′-dimethyl-15-dehydroprostaglandin B1 (di-Calciphor (cas 135608-06-9)) in cerebral ischemia

Add time:08/14/2019    Source:sciencedirect.com

Post-ischemic treatment of di-Calciphor (16,16′-dimethyl-15-dehydroprostaglandin B1) significantly improves animal survival and prevents ischemia-induced neurodegeneration of vulnerable forebrain regions assessed with histochemical and biochemical techniques in gerbils. Neuronal degeneration seen by Cresyl violet staining and silver impregnation in the CA1 sector of the hippocampus and the dorso-lateral sector of the striatum was significantly reduced in animals treated with di-Calciphor. In addition, the early onset of selective degradation of calpain I substrates spectrin and microtubule-associated protein (MAP2) in these same vulnerable regions was prevented. The lack of adverse side effects may facilitate the potential therapeutic use of this drug in preventing neuronal damage caused by stroke.

We also recommend Trading Suppliers and Manufacturers of di-Calciphor (cas 135608-06-9). Pls Click Website Link as below: cas 135608-06-9 suppliers

Prev:Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide
Next:Treatment of severe brain ischemia with di- and tri-Calciphor (dimer and trimer of 16,16′-dimethyl prostaglandin B1))